ProQR Therapeutics NV
PRQR1.500USD
+0.040+2.74%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
161.57MMarket Cap
LossP/E TTM
More Details of ProQR Therapeutics NV Company
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV Info
Ticker SymbolPRQR
Company nameProQR Therapeutics NV
IPO dateSep 18, 2014
CEOde Boer (Daniel Anton)
Number of employees166
Security typeOrdinary Share
Fiscal year-endSep 18
AddressZernikedreef 9
CityLEIDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code2333 CK
Phone31881667000
Websitehttps://www.proqr.com/
Ticker SymbolPRQR
IPO dateSep 18, 2014
CEOde Boer (Daniel Anton)
Company Executives of ProQR Therapeutics NV
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
+824388.00%
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Eli Lilly and Company
16.04%
Van Herk Investments
14.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
Other
54.92%
Shareholders
Shareholders
Proportion
Eli Lilly and Company
16.04%
Van Herk Investments
14.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
5.09%
Affinity Asset Advisors LLC
3.42%
Other
54.92%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.45%
Corporation
16.07%
Family Office
14.60%
Investment Advisor
10.96%
Investment Advisor/Hedge Fund
5.66%
Research Firm
3.13%
Individual Investor
2.03%
Other
29.10%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
118
40.27M
38.22%
-4.52M
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.25M
5.94%
-348.47K
-5.28%
Sep 30, 2025
Privium Fund Management BV
5.00M
4.74%
+725.00
+0.01%
Sep 30, 2025
Affinity Asset Advisors LLC
3.60M
3.42%
+100.49K
+2.87%
Sep 30, 2025
abrdn Inc.
2.30M
2.18%
+448.48K
+24.24%
Sep 30, 2025
Morgan Stanley & Co. LLC
2.89M
2.75%
-171.79K
-5.61%
Sep 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
--
--
Sep 30, 2025
Kynam Capital Management LP
1.65M
1.57%
--
--
Sep 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
Proportion0.01%
Avantis International Small Cap Value ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
